Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of different administration methods of sacubitril/valsartan on blood pressure variability and cardiac remodeling in hypertension
ChiCTR2300072128Phase 4Not yet recruiting
- Sponsor
- Shaanxi Provincial People's Hospital
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of sacubitril + valsartan in hypertension (HTN) (3 arms), sponsored by Shaanxi Provincial People's Hospital. Primary endpoints: Change in morning blood pressure at 24 weeks and Change in nocturnal blood pressure at 24 weeks. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
sacubitril + valsartan
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on ChiCTR2300072128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072128.